Drug Trial Radar · NCT06239480
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
51
Actual
Start
Jul 31, 2024
Primary completion
Jan 14, 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Palvella Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- FDA Office of Orphan Products Development
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of continuing on treatment for \>24 weeks.
Conditions
- Microcystic Lymphatic Malformation
Interventions
QTORIN 3.9% Rapamycin Anhydrous GelDrug
QTORIN 3.9% Rapamycin Anhydrous Gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)Time frame: At Week 24
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Orange County
Irvine, California
Stanford University
Palo Alto, California
Children's Healthcare of Atlanta
Atlanta, Georgia
Minnesota Clinical Study Center
New Brighton, Minnesota
Mayo Clinic
Rochester, Minnesota
Vascular Birthmark Institute
New York, New York
University of North Carolina
Chapel Hill, North Carolina
Cincinnati Children's Hospital
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Penn State Hershey Medical Center
Hershey, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Vanderbilt Children's Hospital
Nashville, Tennessee
University of Texas, Dell Children's
Austin, Texas
Texas Children's Hospital
Houston, Texas
University of Utah Health
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.